Current stock page

Catalysts

RCUS Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

RCUSArcus Biosciences, Inc.

Healthcare / Biotechnology

Low Priority

Relative Laggard

BearishEdge 2/10
$17.43−$0.34 (−1.91%)

Latest quote

  • Momentum
    34
  • Value
    43
  • Quality
    41
  • Risk resilience
    42
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 24, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 39/100

Momentum 34/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment -2.16%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 34/100AIQ Edge 2/10 Relative Laggard
Beat rate
63%
5 of 8 reported periods
Average surprise
+14.3%
Across covered historical reports
Latest result
-12.3%
Nov 4, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 4, 2026—-$0.89-$1.00-12.3%$7.58M$9M
Aug 5, 2026—-$0.89-$0.72+19.2%$21.98M$41M
May 5, 2026—-$0.92-$1.02-10.9%$29.48M$17M
Feb 25, 2026—-$1.11-$0.89+19.8%$35.71M$33M
Oct 28, 2025—-$1.33-$1.27+4.5%$24.94M$26M
Aug 6, 2025—-$1.14-$0.08+93.4%$32.48M$160M
May 6, 2025—-$1.02-$1.14-11.8%$37.36M$28M
Feb 25, 2025—-$1.17-$1.03+12.0%$29.38M$26M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
13
Buy
2
Hold
12-month analyst target
$45.50
+161.04% versus current price
Based on 15 analyst observations. Targets are estimates, not predictions.
Low target
$41.00
+135.23% vs latest price
Average target
$45.50
+161.04% vs latest price
High target
$50.00
+186.86% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 24, 2027

Next known earnings or reporting date.

EPS estimate-$0.87

Current analyst expectation for the upcoming report.

Revenue estimate$5.11M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score34

Where event reaction would show up first.

AIQ score39/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
15
Average target
$45.50
Target upside
161.04%
Target range
$41.00 - $50.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
3
Neutral
0
Negative
2
zacks.com · Nov 4, 2026

Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Lags Revenue Estimates

Arcus Biosciences (RCUS) delivered earnings and revenue surprises of -8.70% and -24.24%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

gurufocus.com · Oct 21, 2026

Arcus Biosciences (RCUS) Shares Plunge Nearly 20% Amid Clinical Data Release and Stock Offering

On October 21, 2026, Arcus Biosciences Inc (NYSE: RCUS) experienced a sharp decline in its stock price, dropping nearly 20% to close at $19.10 following the rel

gurufocus.com · Oct 21, 2026

RCUS Maintained by Citigroup -- Price Target Raised to $50.00

Arcus Biosciences (RCUS) Analyst Rating Update On October 16, 2023, Citigroup maintained a Buy rating on Arcus Biosciences (RCUS), indicating confidence in t

seekingalpha.com · Oct 21, 2026

Arcus Biosciences: Encouraging Casdatifan Data, But The Hard Part Still Ahead (NYSE:RCUS)

Arcus Biosciences casdatifan combinations showed superior or competitive PFS and response rates versus historical benchmarks. Learn why RCUS stock is a buy.

seekingalpha.com · Oct 20, 2026

Arcus Biosciences, Inc. (RCUS) Discusses New Data on Casdatifan for Kidney Cancer Across Multiple Lines of Therapy Transcript

Arcus Biosciences, Inc. (RCUS) Discusses New Data on Casdatifan for Kidney Cancer Across Multiple Lines of Therapy October 20, 2026 8:30 AM EDTCompany...

Open full news and sentiment

RCUS Catalysts FAQ

What are the next catalysts for RCUS stock?

RCUS's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move RCUS stock?

Upcoming events that could move RCUS include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could RCUS's next earnings report affect the stock?

RCUS's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive RCUS stock higher?

RCUS could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt RCUS stock?

RCUS could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.